L-deprenyl 1 mg/kg daily versus placebo survival study in 82 paired beagles
Eighty-two beagles aged 2.8 to 16.4 years were allotted to 41 pairs and given placebo or 1 mg/kg L-deprenyl orally once daily for 2 years and 10 weeks. Across all dogs there was no significant difference in survivorship between the groups. In a subset of elderly dogs aged 10 to 15 years at the start who received tablets for at least 6 months, L-deprenyl-treated dogs survived longer (p < 0.05), with 12 of 15 surviving to the end of the study versus 7 of 18 on placebo (P=0.017).
Record
| Design | controlled trial |
|---|---|
| Status | completed |
| Intervention | L-deprenyl |
| Intervention class | drug |
| Comparator | placebo |
| Dose regimen | 1 mg/kg L-deprenyl orally once daily |
| Duration | 2 years and 10 weeks |
| Dogs | 82 |
| Population note | 82 beagles allotted to 41 pairs; elderly subset aged 10-15 years at start and treated for at least 6 months: 15 L-deprenyl and 18 placebo dogs |
| Breed | beagle |
| Age | 2.8 to 16.4 years |
| Other | Weight 6.3 to 15.8 kg |
| Primary outcome | Survivorship (survival to the conclusion of the study) |
| Result (as reported) | When survivorship for all dogs in the study was analyzed there was no significant difference between the L-deprenyl and placebo treated groups. In the subset of elderly dogs, dogs in the L-deprenyl group survived longer (p < 0.05) than dogs in the placebo group: twelve of 15 (80%) L-deprenyl dogs survived to the conclusion of the study, in contrast to only 7 of 18 (39%) of the dogs who received placebo (P=0.017). |
| Tags | l-deprenyl, lifespan, beagle, drug, placebo-controlled |
Notes: The abstract describes pair allotment and a placebo comparator but does not state randomization, blinding, the housing setting or the funder. The survival benefit is reported in an elderly subset analysed within the same study.
Sources and verbatim quotes
Treatment with L-deprenyl prolongs life in elderly dogs. (1997) PMID 9307048 (results)
Eighty two beagle dogs ranging in age from 2.8 to 16.4 years and in weight from 6.3 to 15.8 kg were allotted to 41 pairs and administered placebo or 1 mg/kg L-deprenyl orally once daily for 2 years and 10 weeks.
When survivorship for all dogs in the study was analyzed there was no significant difference between the L-deprenyl and placebo treated groups
To assess whether L-deprenyl treatment begun in later life might enhance canine longevity in a fashion similar to that documented in rodents we also examined survival in a subset of elderly dogs who were between the ages of 10 and 15 yrs at the start of tablet administration and who received tablets for at least 6 months.
In this subset, dogs in the L-deprenyl group survived longer (p < 0.05) than dogs in the placebo group.
Twelve of 15 (80%) dogs in the L-deprenyl group survived to the conclusion of the study, in contrast to only 7 of 18 (39%) of the dogs who received placebo (P=0.017).
the findings reported herein suggest daily oral administration of 1 mg/kg L-deprenyl prolongs life when begun in relatively healthy dogs 10-15 years of age
Reproduce: canine_trial_search(trial_id="l-deprenyl-beagle-survival-1997") in dog-geroscience-mcp; dataset canine-trial-registry.